Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

NCT06441747 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

NETWORK

Sponsor class

Conditions

Cholangiocarcinoma

Interventions

DRUG: Durvalumab
DRUG: Olaparib

Sponsor

Australasian Gastro-Intestinal Trials Group

Collaborators

[object Object]
[object Object]